MRNS - MARINUS PHARMACEUTICALS INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals Inc. | Benzinga
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
- Do you, or did you, own shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
- Did you purchase your shares between March 17, 2021 and May 7, 2024, inclusive?
- Did you lose money in your investment in Marinus Pharmaceuticals, Inc.?
- Do you want to discuss your rights?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS) between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
If you purchased or acquired Marinus securities, and/or would like to discuss your legal rights and options please visit Marinus Pharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
Marinus describes itself as a "commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare ...
MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.>Full story available on Benzinga.com